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Blood cell counts and lymphocyte subsets of patients admitted
during the COVID-19 pandemic: a prospective cohort study
Aberrant blood cell counts, most prominently lymphopenia,
have been identified as markers of the degree of severity of
coronavirus disease 2019 (COVID-19).1–5 However, most of
these studies lack comparison to a COVID-19-negative con-
temporary control group. Additionally, the longitudinal com-
position and dynamics of lymphocyte subsets in patients
with COVID-19 are insufficiently characterised. We per-
formed a prospective cohort study, in which we compared
blood cell and lymphocyte subset counts between (i) hospi-
tal-admitted patients with COVID-19 and a large contempo-
rary COVID-19-negative hospitalised control group, and (ii)
non-critically and critically ill patients with COVID-19. In
addition, we evaluated the impact of these parameters on the
in-hospital mortality rate of COVID-19. Finally, we assessed
the dynamics of lymphocyte reconstitution in patients with
COVID-19 over time.
Results
From 1 March until 1 May 2020, all adult patients who were
admitted to our specialised COVID-19 ward on suspicion of
COVID-19 and tested by polymerase chain reaction (PCR)
for severe acute respiratory syndrome coronavirus-2 (SARS-
CoV-2) were included. Follow-up lasted until discharge,
death or data lock. A total of 551 patients were enrolled.
COVID-19 was diagnosed in 197 patients, either by PCR
(158/197, 80%) or by high-resolution computed tomography
imaging (39/197, 20%). Based on intensive care unit admis-
sion or death during hospital admission, 82/197 (42%) of
these patients with COVID-19 were retrospectively labelled as
‘critically ill’. COVID-19 was ruled out in the remaining 354
patients (controls). The definitive diagnoses in the control
group were heterogeneous, ranging from bacterial infections
to congestive heart failure and cancer. Baseline characteristics
and outcomes of the included patients are presented in
Table S1.
Complete routine blood analysis was performed on the
day of admission for 349/354 controls, 114/115 non-critically
and 78/82 critically ill patients with COVID-19 (Table 1,
Table S2). Compared to the controls, patients with COVID-
19 had a lower prevalence of anaemia and leucocytosis
(>11 9 109/l) and a higher prevalence of thrombocytopenia
(<150 9 109/l) (Fig 1A–C). Furthermore, anaemia was sig-
nificantly more prevalent in critically ill patients with
COVID-19, compared to non-critically ill patients with
COVID-19. Leucocyte differentiation was performed within
the first few days of admission for 152/354 controls, 76/115
non-critically and 46/82 critically ill patients with COVID-19
(Table 1, Table S2). The median lymphocyte counts were
not significantly different between the controls and the
patients with COVID-19, or between non-critically and criti-
cally ill patients with COVID-19 (Fig 1D). Correspondingly,
the prevalence of lymphopenia (<10 9 109/l) was similar
between the controls and patients with COVID-19, and
between non-critically and critically ill patients with COVID-
19. Lymphopenia, defined by a less stringent threshold
(<15 9 109/l), was present in most patients, but more
prevalent in patients with COVID-19. The controls, com-
pared to the patients with COVID-19, had a higher mean
neutrophil count (Figure S1A). Additionally, compared to
non-critically ill patients with COVID-19, the mean neu-
trophil count was higher in critically ill patients with
COVID-19.
In 25/354 controls, 39/115 non-critically and 40/82 criti-
cally ill patients with COVID-19, lymphocyte subsets were
quantified by immunophenotyping during admission
(Table 1, Table S2). A list of diagnoses in the 25 controls
from whom immunophenotyping data were obtained is pre-
sented in Table S3. The median CD4+- and CD8+-T-lympho-
cyte counts were similar between the controls, non-critically
and critically ill patients with COVID-19 (Fig 1D,F). The
majority of both controls and patients with COVID-19 had
diminished CD8+-T-cell counts (<200/mm2), but this pro-
portion was larger in the COVID-19 group. Compared to
non-critically ill patients with COVID-19, critically ill
patients with COVID-19 had a higher mean CD4/CD8 ratio
(Figure S1C) and a lower median natural killer (NK) cell
count (Figure S1D).
To assess the impact of blood cell and lymphocyte subset
counts on the in-hospital mortality risk in patients with
COVID-19, we performed univariable survival analyses (Fig-
ure S2). Patients with thrombocytopenia or leucocytosis at
admission had an increased risk of in-hospital mortality (Fig-
ure S2A,B). Although lymphopenia (stringently or leniently
defined) was not predictive of in-hospital mortality for
COVID-19 (not shown), the presence of CD4+-T-lymphope-
nia (<300/mm2) was associated with an increased risk of in-
hospital mortality (Figure S2C).
Immunophenotyping was not performed at a standardised
time point for each patient. Additionally, immunophenotyping
correspondence
ª 2020 British Society for Haematology and John Wiley & Sons Ltd doi: 10.1111/bjh.16983
was performed two- or three-times in 29 and four patients
with COVID-19 respectively. This allowed us to perform a lon-
gitudinal analysis in which we included all patients with
repeated measurements and defined the date of first symptom
as t0. Although patients with COVID-19 generally had lym-
phopenia at admission (Fig 1D), the lymphocyte counts grad-
ually increased to reference values around disease day 14
(Fig 1G). CD4+-T lymphocytes experienced a similar rise after
2 weeks (Fig 1H), but CD8+-T-lymphocyte reconstitution was
much slower, and average CD8+-T-cell counts did not reach
normal limits even after 40 days (Fig 1I).
Discussion and conclusions
The core strength of our present study is the inclusion of a
large, contemporary, COVID-19-negative control population,
which allowed us to critically reappraise the haematological
features of patients with COVID-19. At admission, anaemia,
leucocytosis and neutrophilia were more prevalent in the
controls than in the patients with COVID-19. In agreement
with recent reports, thrombocyte counts were lower in
patients with COVID-19, and thrombocytopenia was associ-
ated with an increased risk of in-hospital mortality.6,7
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Fig 1. Routine blood analysis, leucocyte differentiation and immunophenotyping. (A–F) Dot plots with routine blood analysis, leucocyte differen-
tiation and immunophenotyping results for controls, non-critically and critically ill patients with COVID-19. Each dot represents a single mea-
surement. Upper and lower hinges represent the IQR, whereas the whiskers extend 15-times the IQR. Dotted lines represent the normal
reference range. (A–C) routine blood analysis results at day of admission. Significance tested with Student’s t-test. (D) total lymphocyte counts,
quantified by leucocyte differentiation within the first few days of admission. Significance tested with Mann–Whitney–Wilcoxon test. (E,F)
CD3+CD4+ and CD3+CD8+-T-lymphocyte counts, quantified by immunophenotyping. Significance tested with Mann–Whitney–Wilcoxon test. (G,
H) Spaghetti plots illustrating lymphocyte subset counts over time in COVID-19-positive patients, with t0 defined as start of symptoms. Grey
lines represent repeated measurements in individual patients, the black dashed line represent the summarised trend of all individual patients and
the black dotted lines denote the upper and lower limit of the normal reference range, uncorrected for age. (G) Total lymphocyte counts in
patients withCOVID-19 over time in patients with repeated measurements, including both leucocyte differentiation and immunophenotyping
results. (H,I) lymphocyte subset counts over time in COVID-19-positive patients. Only patients with repeated immunophenotyping measurements
were included. COVID-19; coronavirus disease 2019; Hb, haemoglobin; IQR, interquartile range; ns, not significant.
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Lymphopenia, previously presented as a hallmark of
COVID-19,1,8,9 is a common feature of critical illness in gen-
eral.10 Indeed, in our present cohort, neither the median
lymphocyte counts nor the prevalence of lymphopenia
(<10 9 109/l) were different between the patients with
COVID-19 and the controls. This suggests that lymphopenia
per se, at least stringently defined, is not a discriminatory fea-
ture of COVID-19.
Unfortunately, we were only able to perform immunophe-
notyping in a proportion of patients. Furthermore,
immunophenotyping could not be performed at a standard-
ised time point, which bears the risk of comparing patients
at different stages of their disease. Nevertheless, the range in
timing of the immunophenotyping, in combination with
repeated sampling in some patients, allowed us to demon-
strate that in patients with COVID-19, reconstitution of
CD4+-T lymphocytes starts around disease day 14, whereas
CD8+-T-lymphocyte reconstitution was much slower. This
possibly reflects the functional exhaustion reported in these
cells in the context of COVID-19.8
In conclusion, we demonstrate that red cell, white cell,
and platelet counts are significantly different between
COVID-19-positive and -negative patients, whereas lym-
phopenia is not a distinguishing feature of COVID-19. Our
present data help to identify patients at higher risk of a criti-
cal disease course, who could potentially most benefit from
pre-emptive interventions.
Methods
For the methods section, please see the supporting material.
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Table 1. Blood cell and lymphocyte subset counts of the patients with COVID-19 and the controls.
Variable
Controls (no COVID-19),
n = 354
Patients with COVID-19,
n = 197 P
Haemoglobin, mmol/l, mean (95% CI) 78 (76–79) 82 (80–84) <0001
Anaemia, n (%) 153 (43) 58 (30) 0003
N/A, n 2 4
Thrombocyte count, 9 109/l, mean (95% CI) 262 (251–274) 224 (210–237) <0001
Thrombocytopenia, n (%) 46 (13) 39 (20) 003
N/A, n 5 5
Leucocyte count, 9 109/l, mean (95% CI) 120 (114–126) 82 (71–92) <0001
Leucocytosis, n (%) 167 (48) 34 (18) <0001
N/A, n 3 4
Neutrophil count, 9 109/l, mean (95% CI) 89 (80–98) 62 (56–68) <0001
Neutrophilia, n (%) 82 (54) 36 (30) <0001
N/A, n 202 75
Lymphocyte count, 9 109/l, median (95% CI) 11 (10–13) 10 (09–11) 9 109/l 026
Lymphopenia <10 9 109/l, n (%) 77 (51) 73 (60) 013
Lymphopenia <15 9 109/l, n (%) 107 (70) 101 (83) 002
N/A, n 202 75
CD4+-T-lymphocyte count, /mm2, median (95% CI) 589 (444–861) 581 (486–696) 086
Below reference range, n (%) 5 (20) 16 (20) 098
N/A, n 329 118
CD8+-T-lymphocyte count, /mm2, median (95% CI) 133 (72–278) 81 (64–101) 025
Below reference range, n (%) 17 (68) 70 (89) 002
N/A, n 329 118
CD4/CD8 ratio, mean (95% CI) 149 (58–239) 127 (90–163) 055
B-lymphocyte count, /mm2, median (95% CI) 143 (86–204) 143 (119–174) 085
Below reference range, n (%) 10 (40) 33 (42) 088
N/A, n 329 118
Igj/Igk light chain ratio, median (95% CI) 16 (14–21) 15 (14–16) 055
NK cell count, /mm2, median (95% CI) 196 (138–259) 164 (132–198) 033
Below reference range, n (%) 7 (28) 23 (29) 086
N/A, n 329 118
Routine blood counting, leucocyte differentiation and immunophenotyping results of patients with COVID-19 and COVID-19-negative controls.
P values were calculated using Welch’s t-test and a Mann–Whitney–Wilcoxon test for normally distributed and non-normally distributed continu-
ous variables, respectively, and using a chi-square test for categorical variables. 95% CI, 95% confidence interval; COVID-19, coronavirus disease
2019; Ig, immunoglobulin; N/A, not available; NK cell, natural killer cell.
Correspondence
ª 2020 British Society for Haematology and John Wiley & Sons Ltd 3
Baalen, Eva Jansen, €Omer Balak, Peter E. Westerweel and Mark-
David Levin were involved in patient inclusion and data acquisi-
tion. Linda H. A. de Bruin and Jurgen A. Riedl performed the
flow cytometry. Paul J. Hengeveld, Aaram O. Khader, Inge G. P.
Geelen, Eske A. van Baalen, Eva Jansen and Mark-David Levin
extracted the data from the electronic patient files. Paul J.
Hengeveld, Nathalie I. Bouwer, Anton W. Langerak and Mark-
David Levin advised and performed the data analysis. Paul J.
Hengeveld wrote the manuscript. All authors critically reviewed
and approved the final manuscript.
Conflict of Interest
The authors do not have any conflict of interest to report.
Paul J. Hengeveld1,2
Aaram O. Khader1
Linda H. A. de Bruin3
Inge G. P. Geelen1
Eske A. van Baalen1
Eva Jansen1
Nathalie I. Bouwer1
€Omer Balak4
Jurgen A. Riedl3
Anton W. Langerak2
Peter E. Westerweel1
Mark-David Levin1
1Department of Internal Medicine, Albert Schweitzer Hospital,
Dordrecht, 2Laboratory Medical Immunology, Erasmus MC, Rotterdam,
3Result Laboratory, Albert Schweitzer Hospital and 4Department of
Pulmonology, Albert Schweitzer Hospital, Dordrecht, the Netherlands.
E-mail: p.j.hengeveld@asz.nl
Keywords: COVID-19, lymphocytes, lymphopenia, subsets,
immunophenotyping
Supporting Information
Additional supporting information may be found online in
the Supporting Information section at the end of the article.
Fig S1. Routine blood analysis, leucocyte differentiation
and immunophenotyping.
Fig S2. Survival analysis in COVID-19-positive patients.
Table S1. Baseline clinical characteristics and outcomes.
Table S2. Blood cell- and lymphocyte subset counts of
non-critically and critically ill patients with COVID-19.
Table S3. Definitive diagnoses in controls who underwent
immunophenotyping.
Data S1. Supplementary methods.
References
1. Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN,
Politou M, et al. Hematological findings and complications of COVID-19.
Am J Hematol. 2020;95:834–47.
2. Wan S, Yi Q, Fan S, Lv J, Zhang X, Guo L, et al. Relationships among
lymphocyte subsets, cytokines, and the pulmonary inflammation index in
coronavirus (COVID-19) infected patients. Br J Haematol. 2020;189:428–
37.
3. Wang F, Nie J, Wang H, Zhao Q, Xiong Y, Deng L, et al. Characteristics
of peripheral lymphocyte subset alteration in COVID-19 pneumonia. J
Infect Dis. 2020;221:1762–9.
4. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and out-
comes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan,
China: a single-centered, retrospective, observational study. Lancet Respir
Med. 2020;8:475–81.
5. Zhao Q, Meng M, Kumar R, Wu Y, Huang J, Deng Y, et al. Lymphopenia
is associated with severe coronavirus disease 2019 (COVID-19) infections:
a systemic review and meta-analysis. Int J Infect Dis. 2020;96: 131–5.
6. Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with sev-
ere coronavirus disease 2019 (COVID-19) infections: a meta-analysis. Clin
Chim Acta. 2020;506:145–8.
7. Maquet J, Lafaurie M, Sommet A, Moulis G, Alvarez M, Amar J, et al.
Thrombocytopenia is independently associated with poor outcome in
patients hospitalized for COVID-19. Br J Haematol. 2020 [Epub ahead of
print]. DOI: https://doi.org/10.1111/bjh.16950
8. Zheng M, Gao Y, Wang G, Song G, Liu S, Sun D, et al. Functional
exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol
Immunol. 2020;17:533–5.
9. Bermejo-Martin JF, Almansa R, Menendez R, Mendez R, Kelvin DJ, Tor-
res A. Lymphopenic community acquired pneumonia as signature of sev-
ere COVID-19 infection. J Infect. 2020;80:e23–e24.
10. Hohlstein P, Gussen H, Bartneck M, Warzecha KT, Roderburg C, Buend-
gens L, et al. Prognostic relevance of altered lymphocyte subpopulations in
critical illness and sepsis. J Clin Med. 2019;8:353.
Correspondence
4 ª 2020 British Society for Haematology and John Wiley & Sons Ltd
